Vanguard Group Inc. Has $38.91 Million Holdings in Evolus, Inc. $EOLS

Key Points

• Vanguard Group Inc. increased its stake in Evolus, Inc. by 2.0%, now holding over 3.2 million shares valued at approximately $38.9 million.
• In the recent quarter, **institutional investors** own a staggering 90.69% of Evolus, indicating strong support from major financial firms.
• Analysts' ratings are mixed, with an average target price of $21.25, while Needham & Company maintains a "hold" rating, and HC Wainwright has lowered their price target to $20.00.

Vanguard Group Inc. increased its holdings in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 2.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,234,068 shares of the company's stock after buying an additional 62,664 shares during the quarter. Vanguard Group Inc. owned 5.02% of Evolus worth $38,906,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Caligan Partners LP raised its holdings in Evolus by 22.7% during the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock worth $29,724,000 after buying an additional 498,900 shares during the period. Allostery Investments LP acquired a new stake in shares of Evolus in the 4th quarter valued at about $4,760,000. Millennium Management LLC raised its stake in shares of Evolus by 29.1% in the 4th quarter. Millennium Management LLC now owns 1,368,423 shares of the company's stock valued at $15,107,000 after purchasing an additional 308,753 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Evolus by 63.2% in the first quarter. Assenagon Asset Management S.A. now owns 710,713 shares of the company's stock valued at $8,550,000 after purchasing an additional 275,260 shares in the last quarter. Finally, Soros Fund Management LLC boosted its position in shares of Evolus by 29.4% during the fourth quarter. Soros Fund Management LLC now owns 1,100,000 shares of the company's stock worth $12,144,000 after buying an additional 250,000 shares during the period. Institutional investors own 90.69% of the company's stock.

Evolus Stock Performance

NASDAQ EOLS traded up $0.11 during trading on Friday, reaching $7.63. 472,060 shares of the company's stock were exchanged, compared to its average volume of 2,259,618. The business has a 50 day moving average price of $8.43 and a 200-day moving average price of $10.44. The company has a debt-to-equity ratio of 22.00, a current ratio of 2.27 and a quick ratio of 1.86. Evolus, Inc. has a fifty-two week low of $5.71 and a fifty-two week high of $17.82.

Analysts Set New Price Targets

A number of brokerages recently issued reports on EOLS. Needham & Company LLC reissued a "hold" rating and issued a $22.00 target price on shares of Evolus in a research report on Wednesday, August 6th. HC Wainwright dropped their target price on Evolus from $27.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Wall Street Zen lowered Evolus from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Finally, BTIG Research decreased their price objective on Evolus from $21.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $21.25.

Insiders Place Their Bets

In other Evolus news, Director Albert G. White III purchased 20,000 shares of the stock in a transaction on Monday, June 9th. The shares were purchased at an average price of $9.45 per share, with a total value of $189,000.00. Following the completion of the transaction, the director directly owned 50,378 shares in the company, valued at $476,072.10. This represents a 65.84% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $7.51, for a total value of $42,972.22. Following the transaction, the chief marketing officer directly owned 89,949 shares in the company, valued at approximately $675,516.99. This trade represents a 5.98% decrease in their position. The disclosure for this sale can be found here. Insiders sold 133,627 shares of company stock worth $1,325,764 in the last three months. 5.90% of the stock is owned by corporate insiders.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.